IDH1 mutation in B-ALL is rare. Tissue-agnostic ivosidenib not approved in lymphoid; per...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-IDH1-R132H-B-ALL |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-B-ALL |
| Sources | SRC-CALGB-10403-STOCK-2019 SRC-CIVIC |
Actionability Facts
| Biomarker | BIO-IDH-MUTATION |
|---|---|
| Variant | IDH1 R132H |
| Disease | DIS-B-ALL |
| ESCAT tier | IV |
| Evidence summary | IDH1 mutation in B-ALL is rare. Tissue-agnostic ivosidenib not approved in lymphoid; per usual B-ALL pediatric/adult protocol. |
Notes
ESCAT IV.
Used By
No reverse references found in the YAML corpus.